North China Valuation Multiples
North China is valued at $1.2B as of November 2026, a 2.1x revenue multiple. In the last fiscal year, North China revenue was $1.4B and North China EBITDA was $246M.
North China Overview
About North China
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
Founded
1992
HQ
Employees
14.8K
Website
Financials (Last FY)
EV
$2.9B
Valuation Multiples
Start free trial
North China Financials
North China reported last fiscal year revenue of $1.4B and EBITDA of $246M.
In the same fiscal year, North China generated $430M in gross profit, $246M in EBITDA, and $27M in net income.
North China P&L
In the most recent fiscal year, North China reported revenue of $1.4B and EBITDA of $246M.
North China is profitable as of last fiscal year, with gross margin of 31%, EBITDA margin of 18%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
North China Stock Performance
North China has current market cap of $1.2B, and enterprise value of $2.9B.
Market Cap Evolution
North China's stock price is $0.72.
North China share price increased by 4.9% in the last 30 days.
North China has an EPS (earnings per share) of $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $1.2B | -0.0% | 4.9% | - | - | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNorth China Valuation Multiples
North China trades at 2.1x EV/Revenue multiple, and 11.7x EV/EBITDA.
North China Financial Valuation Multiples
As of November 9, 2026, North China has market cap of $1.2B and EV of $2.9B.
North China has a P/E ratio of 44.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified North China Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
North China Margins & Growth Rates
In the most recent fiscal year, North China reported gross margin of 31%, EBITDA margin of 18%, and net margin of 2%.
North China Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
North China Operational KPIs
North China's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
North China Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all North China competitors and their valuation data. Start Free Trial | ||||||
Investments by North China
North China has invested in 1 company to date.
Latest investment by North China was on October 28th 2026. North China invested in Anyuan Pharmaceuticals in their Strategic investment round.
Latest Investments by North China
| Description | Anyuan Pharmaceuticals, operating as Ampsource Biopharma Shanghai, is a biotechnology company that discovers and develops long-acting protein and antibody therapeutics. Its technology base includes a high-affinity antibody platform, a high-titer CHO cell production system, linker and conjugation platforms, and AI applied to monoclonal antibody design. The pipeline covers oncology, autoimmune diseases, hemophilia and metabolic disorders, with candidates such as AP061, AP017, AP025 and AP026. The company is based in the Pudong New Area of Shanghai. Its website states it was established in 2012, while other records give 2016. |
| HQ Country | |
| HQ City | Shanghai |
| Deal Date | 28 Oct 2026 |
| Round | Strategic investment |
| Raised | undisclosed |
| Investors | North China |
| Valuation | $78M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all North China investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout North China
| When was North China founded? | North China was founded in 1992. |
| Where is North China headquartered? | North China is headquartered in China. |
| How many employees does North China have? | As of today, North China has over 14K employees. |
| Is North China publicly listed? | Yes, North China is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of North China? | North China trades under 600812 ticker. |
| When did North China go public? | North China went public in 1994. |
| Who are competitors of North China? | North China main competitors include |
| What is the current market cap of North China? | North China's current market cap is $1.2B. |
| What is the current revenue of North China? | North China's last fiscal year revenue is $1.4B. |
| What is the current EV/Revenue multiple of North China? | Current revenue multiple of North China is 2.1x. |
| Is North China profitable? | No, North China is not profitable. |
| How many companies North China has acquired to date? | North China hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies North China has invested to date? | As of November 2026, North China has invested in 1 company. |
| What was the last North China investment? | On 28th October 2026 North China invested in Anyuan Pharmaceuticals, participating in a Strategic investment round at $78M valuation. |
| In what companies North China invested in? | North China invested in Anyuan Pharmaceuticals. |
Lists including North China
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.